<DOC>
	<DOC>NCT01004809</DOC>
	<brief_summary>Post-marketing surveillance(PMS) to monitor the safety and effectiveness of dutasteride in Korean androgenetic alopecia patients</brief_summary>
	<brief_title>AVODARTÂ® Alopecia Post-marketing Surveillance (PMS)</brief_title>
	<detailed_description>An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and effectiveness of dutasteride administered in Korean androgenetic alopecia patients according to the prescribing information</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Men (1841 years of age) with male pattern hair loss (androgenetic alopecia) Subjects with no experience of treatment using dutasteride Subjects who the investigator believes that they can and will comply with the requirements of the protocol Subjects who prescribed with dutasteride according to the Prescribing Information Considering the nature of observational study, GSK Korea encourages the doctors participating in this study to enrol the subjects prescribed with dutasteride following the locally approved Prescribing Information. Subject who give informed consent is enrolled. However, if institution waives the requirement for informed consent, informed consent is not required. In this case, monitoring does not proceed.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Dutasteride</keyword>
</DOC>